Skip to main content
. 2020 Jun 9;69(9):1989–2002. doi: 10.2337/db20-0074

Figure 1.

Figure 1

GIP, GLP-1, plasma glucose, and glucose infused. Plasma GIP (A and B), GLP-1 (C and D), and glucose (E and F) vs. time during the 2-h two-step glucose clamp in 10 HNF1A mutation carriers and 10 control subjects without diabetes. Accumulated glucose infused at time 60 min and 120 min (G and H) (subtracted bolus given at time 60 min) in HNF1A mutation carriers (G) and control subjects without diabetes (H). Data are presented as mean ± SD (A–F) and mean ± SEM (G and H). Continuous infusions of saline (NaCl), GIP, or GLP-1 were started at time 0 min preceded by either single-dose SU 1 mg glimepiride or placebo (PLA) at time −90 min. Symbols show significant differences (P < 0.05) between interventions: *significantly greater than PLA+NaCl; †significantly greater than SU+NaCl; ‡significantly greater than PLA+GIP; §significantly greater than PLA+GLP-1. FPG, fasting plasma glucose.